Vanguard Group Inc. grew its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 10.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 145,161 shares of the medical instruments supplier’s stock after purchasing an additional 13,263 shares during the period. Vanguard Group Inc. owned approximately 3.86% of Mesa Laboratories worth $20,804,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Strs Ohio lifted its stake in shares of Mesa Laboratories by 5.6% in the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 100 shares during the last quarter. BT Investment Management Ltd acquired a new position in shares of Mesa Laboratories in the 2nd quarter valued at $277,000. Spark Investment Management LLC acquired a new position in shares of Mesa Laboratories in the 2nd quarter valued at $300,000. Alliancebernstein L.P. lifted its stake in shares of Mesa Laboratories by 52.9% in the 2nd quarter. Alliancebernstein L.P. now owns 2,600 shares of the medical instruments supplier’s stock valued at $373,000 after purchasing an additional 900 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Mesa Laboratories by 2.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,117 shares of the medical instruments supplier’s stock valued at $446,000 after purchasing an additional 71 shares during the last quarter. 68.83% of the stock is currently owned by institutional investors and hedge funds.
Mesa Laboratories, Inc. (NASDAQ:MLAB) opened at $130.21 on Wednesday. Mesa Laboratories, Inc. has a 12 month low of $109.14 and a 12 month high of $169.80. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $480.18, a PE ratio of 33.61 and a beta of 0.49.
Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a return on equity of 14.77% and a net margin of 11.48%. The firm had revenue of $22.95 million for the quarter, compared to analyst estimates of $25.50 million. analysts forecast that Mesa Laboratories, Inc. will post 2.47 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Thursday, November 30th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.49%. The ex-dividend date is Wednesday, November 29th. Mesa Laboratories’s payout ratio is 23.10%.
In related news, Director H Stuart Campbell sold 2,000 shares of the stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $130.42, for a total transaction of $260,840.00. Following the transaction, the director now owns 44,366 shares of the company’s stock, valued at approximately $5,786,213.72. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 15.70% of the stock is currently owned by corporate insiders.
Several equities analysts have recently commented on the company. TheStreet raised Mesa Laboratories from a “c+” rating to a “b” rating in a research note on Monday, November 6th. BidaskClub lowered Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. Finally, Zacks Investment Research lowered Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Friday, November 10th.
TRADEMARK VIOLATION WARNING: “Mesa Laboratories, Inc. (MLAB) Stake Boosted by Vanguard Group Inc.” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://weekherald.com/2017/11/15/mesa-laboratories-inc-mlab-stake-boosted-by-vanguard-group-inc.html.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.